On July 25, 2023 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, reported oral and poster presentations reporting clinical and preclinical data for tumor infiltrating lymphocyte (TIL) therapies at IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Singapore, September 9-12, 2023 (Press release, Iovance Biotherapeutics, JUL 25, 2023, View Source [SID1234633410]). The details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mini Oral Presentation: Multicenter phase II trial of LN-145 TIL cell therapy plus pembrolizumab in patients with ICI-naïve metastatic NSCLC
Presenter: Adam J. Schoenfeld, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center
Session: MA15 – Bringing New Discoveries into Early Phase Clinical Trials
Presentation Date & Time: Tuesday, Sep 12, 2023, 11:15 AM – 11:20 AM SST (Monday, September 11, 2023, 11:15 – 11:20 PM EDT)

Poster Presentation: Successful generation of tumor-infiltrating lymphocytes (TIL) for adoptive cell therapy from mesothelioma
Presenter: Professor Dean Fennell FRCP Ph.D., Melanoma Research Programme, University of Leicester
Session: P2.18 – Mesothelioma, Thymoma, and Other Thoracic Tumors – Clinical
Session Date & Time: Monday, September 11, 2023, 6:00 PM – 7:30 PM SST (Monday, September 11, 2023, 6:00 – 7:30 AM EDT)